Enthera Pharmaceuticals Extends Series A Financing, Raising a Total Of €35m
Enthera Pharmaceuticals Extends Series A Financing, Raising a Total Of €35m Funds to be used to advance restorative therapy for type 1 diabetes and inflammatory bowel disease Largest international VC-backed Series A financing round for a biotech in Italy to date and first ever venture investment in an Italian company by both AbbVie Ventures and Roche Venture Fund Proceeds to be used for clinical proof-of-concept for lead product Ent001 (IGFBP3/TMEM219 inhibitor) for type 1 diabetes, gastrointestinal diseases and progress pipeline assets Enthera Pharmaceuticals ("Enthera"), a biotech company...
Source: finanznachrichten.de